JP2006510740A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510740A5
JP2006510740A5 JP2005507039A JP2005507039A JP2006510740A5 JP 2006510740 A5 JP2006510740 A5 JP 2006510740A5 JP 2005507039 A JP2005507039 A JP 2005507039A JP 2005507039 A JP2005507039 A JP 2005507039A JP 2006510740 A5 JP2006510740 A5 JP 2006510740A5
Authority
JP
Japan
Prior art keywords
composition
ursodeoxycholic acid
bleeding
patient
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005507039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510740A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031989 external-priority patent/WO2004043342A2/en
Publication of JP2006510740A publication Critical patent/JP2006510740A/ja
Publication of JP2006510740A5 publication Critical patent/JP2006510740A5/ja
Pending legal-status Critical Current

Links

JP2005507039A 2002-11-07 2003-10-08 出血と関連した神経系障害を治療する方法 Pending JP2006510740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42521002P 2002-11-07 2002-11-07
US45161503P 2003-03-03 2003-03-03
PCT/US2003/031989 WO2004043342A2 (en) 2002-11-07 2003-10-08 Methods of treating injuries of the nervous system associated with hemorrhage

Publications (2)

Publication Number Publication Date
JP2006510740A JP2006510740A (ja) 2006-03-30
JP2006510740A5 true JP2006510740A5 (enExample) 2006-11-24

Family

ID=32314576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005507039A Pending JP2006510740A (ja) 2002-11-07 2003-10-08 出血と関連した神経系障害を治療する方法

Country Status (8)

Country Link
US (1) US20060135494A1 (enExample)
EP (1) EP1575578B1 (enExample)
JP (1) JP2006510740A (enExample)
KR (1) KR20050103185A (enExample)
AT (1) ATE451108T1 (enExample)
AU (1) AU2003275495A1 (enExample)
DE (1) DE60330501D1 (enExample)
WO (1) WO2004043342A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
CN101035541B (zh) * 2004-08-30 2012-05-30 柳署弘 溶解的udca在局灶缺血模型中的神经保护作用
AU2005295541B2 (en) 2004-10-15 2011-02-17 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20080194531A1 (en) * 2005-02-10 2008-08-14 Steer Clifford J Methods for Treating Visual Disorders
CN101534641A (zh) * 2006-03-22 2009-09-16 哈佛大学校长及研究员协会 治疗高胆固醇血症和动脉粥样硬化的方法和组合物
KR20180029317A (ko) * 2016-09-12 2018-03-21 경상대학교산학협력단 간손상 예방, 개선 또는 치료용 조성물
KR101953298B1 (ko) * 2017-07-18 2019-02-28 의료법인 성광의료재단 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090876A1 (en) * 1991-07-03 1993-01-04 Satoru Nakai Apoptosis regulating composition
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US6544972B1 (en) * 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6555141B1 (en) * 1998-02-27 2003-04-29 Nutramax Laboratories, Inc. L-ergothioneine, Milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage
GB0019290D0 (en) * 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells

Similar Documents

Publication Publication Date Title
JP2021100937A5 (enExample)
JP2005508338A5 (enExample)
EP3332797A3 (en) Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
CA2066403A1 (en) Transmucosal dosage form
EP2269647A3 (de) Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ITRM960479A1 (it) Uso della acetil l-carnitina, della isovaleril l-carnitina, della pro= pionil l-carnitina o dei loro sali farmacologicamente accettabili per
JP2003516325A5 (enExample)
JP2005537268A5 (enExample)
RU2007101039A (ru) Иммуностимулирующие олигонуклеотидные мультимеры
JP2005500357A5 (enExample)
EP2746251A3 (en) Positively charged water-soluble prodrugs of acetaminophen and related compunds with very fast skin penetration rate
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
JP2006510740A5 (enExample)
WO1993000083A1 (en) Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
JP2005506275A5 (enExample)
JP2009517411A5 (enExample)
JP2006515370A5 (enExample)
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
JP2009500045A5 (enExample)
JP2006514681A5 (enExample)
IL194500A (en) A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above
US20100029771A1 (en) Treatment of addictive disorders
JP2002530353A5 (enExample)
EP2382982A3 (en) Neural regeneration peptide and methods for their use in treatment of brain damage
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)